Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2024-01-08 Major Shareholding Noti…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with an 'RNS Number' and contains a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership (crossing thresholds) by an individual or entity. This directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content is a mandatory regulatory filing concerning share ownership changes, making MRQ the most precise classification over the general RNS fallback.
2024-01-08 English
AAV Viral Vector Update
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number' and contains standard regulatory boilerplate language from the London Stock Exchange's RNS service, indicating it is a regulatory announcement. The content is an update on ongoing research ('AAV Viral Vector Update') providing scientific results and management commentary, rather than a full financial report (like 10-K or IR) or a formal meeting material (like DEF 14A or AGM-R). Since it is a specific operational/scientific update disseminated via the RNS system that doesn't fit into the other specific categories (like ER, CT, or DIV), the most appropriate classification is the general regulatory announcement category, RNS.
2024-01-08 English
Oral Delivery Update
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number' and contains standard regulatory boilerplate language at the end, including references to 'RNS, the news service of the London Stock Exchange' and the 'Financial Conduct Authority'. The content itself is a positive update on ongoing research ('Oral Delivery Update') regarding the company's product Nuvec®. This is a specific operational/research update, not a full financial report (10-K, IR), a formal earnings release (ER), or a management discussion (MDA). Since it is a formal announcement disseminated via the RNS system that doesn't fit into the more specific categories like DIRS, DIV, or CAP, it falls best under the general Regulatory Filings category (RNS) as a miscellaneous regulatory announcement.
2023-12-18 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 0546W' on '07 December 2023'. This form is used to report changes in significant share ownership, crossing notification thresholds. This directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the content is specific to a major holding change, making MRQ the most precise classification over the general RNS fallback.
2023-12-07 English
Nuvec® R&D and Strategy Update
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '07 December 2023'. It provides a 'Nuvec® R&D and Strategy Update' from N4 Pharma Plc, detailing ongoing scientific research progress, strategic outlook, and includes commentary from the CEO. The presence of the RNS header and the nature of the content—a specific operational/scientific update rather than a full financial report (like 10-K or IR) or a formal meeting announcement—suggests it is a general regulatory announcement. Since it is not a standard financial report, a management change, a dividend notice, or a specific legal filing, the most appropriate classification is the general regulatory announcement category, RNS, as it is explicitly distributed via the RNS service.
2023-12-07 English
N4 Pharma Launches New Interactive Investor Hub
Report Publication Announcement Classification · 1% confidence The document is an announcement released via RNS (RNS Number: 1106V) on November 30, 2023. The content describes the launch of a new 'Interactive Investor Hub' by N4 Pharma PLC. It details what the hub contains (regulatory announcements, reports, presentations) and how shareholders can sign up. Since the document is short (4301 chars) and its primary purpose is to announce the availability of other corporate information and communication channels, rather than being the report itself (like an ER, IR, or 10-K), it fits the description of a general regulatory announcement or a report publication announcement. Given the options, 'Report Publication Announcement' (RPA) is plausible if the announcement was specifically about publishing a report, but this announcement is about launching a new *platform* that *contains* reports and other materials. The document is a general, non-regulatory press release distributed via RNS ('Reach - Non-Regulatory'). When a filing is a general corporate update that doesn't fit a highly specific category (like DIV, DIRS, ER), the fallback category 'Regulatory Filings' (RNS) is appropriate for miscellaneous regulatory news service releases. However, since the core action is announcing the publication/availability of corporate information (including reports and presentations) through a new channel, 'Report Publication Announcement' (RPA) is a strong candidate, as it often covers announcements about the *means* of accessing information. Given the context of announcing a new investor portal that aggregates reports, RPA seems slightly more specific than the general RNS fallback. Let's re-evaluate the definitions. RPA is 'Announcement regarding the timing, release, or publication of company reports'. This announcement is about launching a hub where reports *will be* available, which aligns well with announcing the publication mechanism. I will classify it as RPA.
2023-11-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.